

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEMPUS AI, INC.,
Petitioner,

v.

GUARDANT HEALTH INC.,
Patent Owner.

IPR2025-01434
Patent 11,149,306

**PATENT OWNER'S
UPDATED EXHIBIT LIST**

Updated Exhibit List

Exhibit No.	Description
2001	Excerpts from File History of U.S. Patent Application No. 16/945,124 (issued as U.S. Patent No.11,149,306)
2002	Excerpts from File History of EP Application No. 20183626.9
2003	Information Disclosure Statement App. No. 17/179,279 which issued as U.S. Patent No. 11,221,144
2004	U.S. Patent No. 11,211,144 to Zhu
2005-2014	Intentionally left blank
2015	Tempus Proposed Claim Constructions, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687
2016	Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market – Leading Guardant 360 Test, Further Extending its Best-In-Class Performance. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx (last viewed on October 20, 2024)
2017	Guardant Health to Showcase New Data at ESMO 2022 Demonstrating Utility of its Portfolio of Blood Tests for Advanced – Stage Cancer Patients. https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-to-showcase-new-data-at-ESMO-2022-demonstrating-utility-of-its-portfolio-of-blood-tests-for-advanced-stage-cancer-patients/default.aspx (last viewed on October 20, 2024)
2018	FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Test. News Provided by U.S. Food and Drug Administration

	https://www.prnewswire.com/news-releases/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test-301108536.html (last viewed October 20, 2024)
2019	GOZILA Study Published in Nature Medicine Shows Patients with Advanced Cancer Who Receive Liquid Biopsy – Guided Treatment Using Guardant360 CDX Survive Twice as Long. https://investors.guardanthealth.com/press-releases/press-releases/2024/GOZILA-Study-Published-in-Nature-Medicine-Shows-Patients-With-Advanced-Cancer-Who-Receive-Liquid-Biopsy-Guided-Treatment-Using-Guardant360-CDx-Survive-Twice-as-Long/default.aspx (last viewed October 20, 2024)
2020	Guardant Health Named to TIME100 Most Influential Companies. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Named-to-TIME100-Most-Influential-Companies/default.aspx (last viewed October 20, 2024)
2021	Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation. https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-and-Foundation-Medicine-Reach-Settlement-in-Digital-Sequencing-Technology-Litigation/default.aspx (last viewed October 20, 2024)
2022	Guardant Health, Inc.’s First Amended Complaint, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687
2023	Jin H. Bae, et al., “CODEC enables ‘single duplex’ sequencing”
2024	Jesse J. Salk, Michael W. Schmitt, and Lawrence A. Loeb, “Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations”
2025	Excerpts from Tempus AI, Inc.’s Preliminary Invalidation Contentions served on August 21, 2025, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687

2026	Excerpts from Tempus AI, Inc.'s First Supplemental Preliminary Invalidity Contentions served on October 6, 2025, <i>Guardant Health, Inc., v. Tempus AI, Inc.</i> , Case 1:24-cv-00687
------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CERTIFICATE OF SERVICE

The undersigned certifies that the foregoing Patent Owner's Updated Exhibit List and accompanying Exhibits 2025-2026 were served on December 01, 2025, on the Petitioner at the electronic correspondence address of the Petitioner as follows:

James Glass
Margaret Shyr
QUINN EMANUEL URQUHART & SULLIVAN LLP
jimglass@quinnemanuel.com
margaretshyr@quinnemanuel.com
qu-tempus-IPRs@quinnemanuel.com

Respectfully submitted,

Date: December 01, 2025

/ Michael T. Rosato /
Michael T. Rosato, Lead Counsel
Reg. No. 52,182